The groundbreaking success of Viagra undeniably reshaped the pharmaceutical landscape, but betting in companies primarily reliant on off-patent versions presents a complex picture. Although early returns were substantial, the cessation of patents and the emergence of cheaper alternatives have eroded sales. Therefore, a thorough evaluation of presen